A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Learn more about Alaunos Therapeutics Inc’s (TCRT) stock grades for Value, Growth, Momentum, Estimate Revisions and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Issac Deleon
| Share Statistics | TCRT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4.1 | $282.4 | 3% |
|
| Shares Out (Mil) | 2.4 | 54.0 | 9% |
|
| Institutional Ownership | 21.6% | 93.1% | 10% |
|
| Float (Mil) | 2.0 | 42.2 | 5% |
|
| Beta | -0.96 | 0.94 | 1% |
|
| Avg Daily Volume (000s) | 12 | 482 | 18% |
|
| Price Change (52-week) |
(24.5%) | 59.9% | 27% |
|
| Growth | TCRT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | 44.5% | (10.1%) | 92% |
|
| EPS (5yr) | 47.9% | 15.9% | 92 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (64.1%) | (15.6%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TCRT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($4) | ($43) | 34% |
|
| EPS (TTM) | ($1.768) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($31) | 28% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $4 | $190 | 5% |
|
| Valuation | TCRT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.27 | 2.84 | 83% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TCRT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (128.3%) | (47.7%) | 4% |
|
| ROE | (185.9%) | (55.0%) | 5% |
|
| Liabilities to Assets | 57.0% | 29.8% | 50% |
|
| F-Score | 1 | 3 | 1% |
|
Alaunos Therapeutics, Inc. did not pass any screens on 9/4/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
